Replies to post #15400 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>What I recall are delays in filings, the EMEA delay in acceptance in only one part of the indication (surgery not childbirth), the inclusion of upfront in the 2007 4Q [guidance] for a deal that did not happen, the partner who backed out, insider selling going into the Ovation deal closing, Russel index delisting occurring at the same time as the Ovation partnership deal announcement, hype regarding imminent FOB partnering, no sales in Europe for Atryn, the poorly chosen partner (LEO), the inadequate upfronts, the list goes on…<

You forgot to mention the $2.9M write-off when GTC’s fill/finish contractor had to destroy some of its ATryn inventory and GTC was unable to recover the loss. The size of this loss seemed trivial at the time, but it doesn’t now.